- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05492110
Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction. (REMEDY-PILOT)
July 18, 2023 updated by: Imperial College London
REducing Microvascular Dysfunction in Patients With Angina, Ischaemia and unobstructED coronarY Arteries - a PILOT Study
To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Symptomatic angina in patients with ischaemia and non-obstructed coronary arteries (INOCA) is common and associated with increased morbidity and adverse outcomes.
Myocardial ischaemia often arises from coronary microvascular dysfunction (CMD).
Current treatments are limited, and novel evidence-based therapies are needed to address this large unmet clinical need.
The Coronary Sinus Reducer (CS Reducer) is a new treatment for refractory angina, which creates a focal narrowing in the coronary sinus that increases back pressure and redistributes blood into ischaemic myocardium at the level of the microcirculation.
However the precise mechanism remains unknown.
This study will be a randomised double-blinded sham-controlled pilot study (REMEDY-PILOT) to confirm acceptability of CS Reducer implantation, demonstrate feasibility to recruit and quantify its effect on myocardial perfusion.
A nested mechanistic substudy within REMEDY-PILOT will test the hypothesis that CS Reducer implantation alters measures of invasive coronary microcirculatory physiology as the mechanistic basis for observed changes in quantitative CMR stress perfusion, symptoms and quality of life.
Study Type
Interventional
Enrollment (Estimated)
54
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ranil de Silva, FRCP, PhD
- Phone Number: +44 2073518626
- Email: r.desilva@imperial.ac.uk
Study Contact Backup
- Name: Kevin Cheng, BM BCh, MRCP
- Phone Number: +44 2073518626
- Email: kevin.cheng@imperial.ac.uk
Study Locations
-
-
-
London, United Kingdom, SW36NP
- Recruiting
- National Heart and Lung Institute (Brompton Campus), Imperial College London
-
Contact:
- Ranil de Silva, FRCP, PhD
- Email: r.desilva@imperial.ac.uk
-
Contact:
- Kevin Cheng, BM BCh, MRCP
- Email: kevin.cheng@imperial.ac.uk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age >18 years
- Ongoing symptomatic angina, CCS Class II-IV, for ≥3 months despite background treatment with at least two anti-anginal drug at the maximal tolerated dose.
- Patients willing to consider no change in anti-anginal drug treatment for the duration of their participation in the trial.
- Unobstructed coronary arteries with ≤30% epicardial stenoses demonstrated on coronary angiography.
- Circumferential subendocardial stress-induced hypoperfusion on CMR (global MPR < 2.5).
- Willingness to comply with the specified follow-up evaluation and to be contactable during the period of the trial.
- Understands the nature of the trial procedures and provides written informed consent.
Exclusion Criteria:
- Epicardial CAD (stenoses > 30%), previous percutaneous coronary intervention (PCI), coronary artery bypass grafting, or myocardial infarction (MI).
- Abnormal coronary sinus anatomy (tortuosity, aberrant branch, persistent left superior vena cava)
- Coronary sinus diameter at site of implant <9.5mm or >13mm
- Mean right atrial pressure <15mmHg at time of implantation
- Any structural heart disease including left ventricular hypertrophy; cardiomyopathy; severe valvular heart disease; previous valve replacement; myocardial bridge on angiography; LVEF<45% by CMR.
- Clinically or angiographically diagnosed coronary vasospasm
- Previous hospitalisation for decompensated heart failure
- Pacemaker or defibrillator electrode in the right atrium, right ventricle or coronary sinus
- Documented arrhythmia requiring planned implantation of a permanent pacemaker or defibrillator
- Chronic kidney disease (creatinine >200 μmol/L; established on renal replacement therapy; functioning renal transplant)
- Haemoglobin <80g/L
- Contraindications to receiving dual anti-platelet therapy
- Severe chronic obstructive pulmonary disease (FEV1 <55% predicted)
- Moribund patients with life expectancy < 1year
- Known allergy to nickel or steel
- Current enrolment in another investigational device or drug trial
- Contraindications to CMR or receiving intravenous adenosine
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CS Reducer implantation
|
The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
|
Sham Comparator: Sham procedure
|
Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
Implantation procedure with no device implanted
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of patients consenting to participate in the study.
Time Frame: 6 months
|
Consent rate
|
6 months
|
Premature withdrawal rate including reasons for withdrawal
Time Frame: 6 months
|
Registry of patients either failing screening or unwilling to consent to full trial
|
6 months
|
Change in myocardial perfusion
Time Frame: 6 months
|
Change at 6 months post randomisation, compared to baseline, in quantitative myocardial perfusion (global myocardial perfusion reserve [MPR]) assessed by cardiac MRI.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Canadian Cardiovascular Society (CCS) Angina Score
Time Frame: 6 months
|
Change in CCS class from baseline to 6 months post-randomisation.
The CCS grading system for angina is a clinical tool used by doctors to assess the degree of severity of a patient's angina.
Possible scores range from Class 0 (asymptomatic angina) to Class IV (angina at rest).
|
6 months
|
Seattle Angina Questionnaire (SAQ) score
Time Frame: 6 months
|
Change in SAQ score from baseline to 6 months.
The Seattle Angina Questionnaire (SAQ) is a disease-specific questionnaire used to quantify patients' symptoms of angina and the extent to which their angina affects their functioning and quality of life.
Possible scores range from 0 (daily angina) to 100 (no angina).
Lower scores indicate worse angina symptoms.
|
6 months
|
Short-form 36 (SF-36)
Time Frame: 6 months
|
Change in SF-36 scores from baseline to 6 months.
Validated questionnaire to assess quality of life.
36 items each scored from 0-100 with higher scores indicating a more favourable health state.
|
6 months
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 6 months
|
Change in HADS score from baseline to 6 months.
Scores range from 0 to 21.
Normal results are indicated by lower scores.
Validated questionnaire to assess psychological wellbeing.
|
6 months
|
6-minute walk test (6MWT)
Time Frame: 6 months
|
Change in exercise capacity from baseline to 6 months.
Distance in metres walked in 6 minutes.
|
6 months
|
BORG scale of perceived exertion
Time Frame: 6 months
|
Change in BORG scale from baseline to 6 months.
Scores range from 0 to 20 (BORG scale) or 0 to 10 (Modified BORG scale).
The higher the self-reported score, the greater perceived exertion.
|
6 months
|
Safety events - rate of major adverse events
Time Frame: 6 months
|
The rate of occurrence of a composite of death, myocardial infarction (MI), pericardial effusion requiring surgical or percutaneous intervention, device embolisation, or BARC 3 or 5 bleeding evaluation in the CS Reducer arm compared to the sham-procedure arm.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in absolute global myocardial perfusion (ml/min/g) at rest and during adenosine stress (transmural, endocardial, epicardial) from baseline to 6 months post-randomisation
Time Frame: 6 months
|
6 months
|
Change in absolute myocardial perfusion (ml/min/g) at rest and during adenosine stress (transmural, endocardial, epicardial) from baseline to 6 months post-randomisation in the distribution territory of the left coronary circulation.
Time Frame: 6 months
|
6 months
|
Change in global endocardial:epicardial perfusion ratio at rest and after adenosine stress from baseline to 6 months post-randomisation
Time Frame: 6 months
|
6 months
|
Change in endocardial:epicardial perfusion ratio at rest and after adenosine stress from baseline to 6 months post-randomisation in the distribution territory of the left coronary circulation.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ranil E de Silva, FRCP, PhD, Imperial College London
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 17, 2023
Primary Completion (Estimated)
April 6, 2025
Study Completion (Estimated)
August 7, 2025
Study Registration Dates
First Submitted
August 4, 2022
First Submitted That Met QC Criteria
August 5, 2022
First Posted (Actual)
August 8, 2022
Study Record Updates
Last Update Posted (Actual)
July 20, 2023
Last Update Submitted That Met QC Criteria
July 18, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21IC7301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
National Heart Centre SingaporeUnknownCoronary Heart DiseaseSingapore
Clinical Trials on Coronary sinus reducer
-
Clinical Hospital Centre ZagrebRecruitingCoronary Artery Disease | Angina PectorisCroatia
-
Tel-Aviv Sourasky Medical CenterNeovasc Inc.Recruiting
-
Regional Cardiology Center, The Copper Health Centre...Recruiting
-
University Medical Centre LjubljanaCompletedRefractory Angina PectorisSlovenia
-
Imperial College LondonMedical Research Council; Imperial College Healthcare Nissen FundRecruitingRefractory AnginaUnited Kingdom
-
Kansas City Heart Rhythm Research FoundationNot yet recruitingHeart Failure With Reduced Ejection FractionUnited States
-
Oslo University HospitalNot yet recruiting
-
University Hospital Inselspital, BerneCompletedIschemia | Coronary Artery Disease | Circulation, Collateral | Coronary Sinus | Collateral Flow IndexSwitzerland
-
Neovasc Inc.Shockwave Medical, Inc.Active, not recruitingAngina Pectoris | Chronic Stable Angina | Angina Pectoris, StableNetherlands, Spain, United Kingdom, Germany, Italy, Switzerland, Belgium, France, Austria
-
Johannes Gutenberg University MainzCompletedMicrovascular Coronary Artery DiseaseGermany